Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients

Journal of Infectious Diseases

Volumn 204, Issue 2, 2011, Pages 237-244

  Reid, Carl E ^a   Li, Huo ^a   Sur, Gargi ^a   Carmillo, Paul ^a   Bushnell, Steven ^a   Tizard, Rich ^a   McAuliffe, Michele ^a   Tonkin, Christopher ^a   Simon, Kenneth ^a   Goelz, Susan ^a   Cinque, Paola ^b   Gorelik, Leonid ^a   Carulli, John P ^a  

^a BIOGEN   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; PROTEIN VP1; VIRUS DNA;

ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOTYPE; HUMAN; JC VIRUS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIRUS CAPSID; VIRUS GENOME;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; BLOOD; CAPSID PROTEINS; DNA, VIRAL; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA;

EID: 79958755750     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir256     Document Type: Article

References (44)

1. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199:837-46.
2. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5:e1000363.
3. Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006; 577:19-45.
4. Grinnell BW, Padgett BL, Walker DL. Distribution of nonintegrated DNA from JC papovavirus in organs of patients with progressive multifocal leukoencephalopathy. J Infect Dis 1983; 147:669-75. (Pubitemid 13088240)
5. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52:253-60. (Pubitemid 29059048)
6. Berger JR, Concha M. Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J Neurovirol 1995; 1:5-18.
7. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004; 17:365-70. (Pubitemid 38720991)
8. Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003; 9(Suppl 1):38-41. (Pubitemid 36656469)
9. Boldorini R, Omodeo-Zorini E, Nebuloni M, et al. Lytic JC virus infection in the kidneys of AIDS subjects. Mod Pathol 2003; 16:35-42. (Pubitemid 36152684)
10. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9:625-36.
11. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425-37.
12. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369-74. (Pubitemid 41132341)
13. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl JMed 2005; 353:375-81. (Pubitemid 41132342)
14. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-8. (Pubitemid 41132340)
15. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:1-8-13.
16. Noseworthy JH, Kirkpatrick P. Natalizumab. Nat Rev Drug Discov 2005; 4:101-2.
17. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-46.
18. Jiang M, Abend JR, Johnson SF, Imperiale MJ. The role of polyomaviruses in human disease. Virology 2009; 384:266-73.
19. Safak M, Khalili K. An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol 2003; 9(Suppl 1):3-9. (Pubitemid 36656463)
20. Yogo Y, Kitamura T, Sugimoto C, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 1990; 64:3139-43. (Pubitemid 20171319)
21. Yogo YS, Sugimoto C. The archetype concept and regulatory region rearrangement. In: Khalili K, Stoner GL, eds: Human polyomaviruses: molecular and clinical perspectives. New York, NY:Wiley-Liss, 2001; 127-48.
22. Gorelik L. In PML patients JC virus (JCV) VP1 protein undergoes selective mutations that change its receptor specificity. J Infect Dis 2011; 204(1):103-14. doi:10.1093/infdis/JIR198.
23. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 2009; 5:e1000368.
24. Zheng HY, Ikegaya H, Takasaka T, et al. Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy. Biochem Biophys Res Commun 2005; 333:996-1002. (Pubitemid 40854255)
25. Zheng HY, Takasaka T, Noda K, et al. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. J Gen Virol 2005; 86:2035-45. (Pubitemid 40916388)
26. Agostini HT, Ryschkewitsch CF, Baumhefner RW, et al. Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy. J Neurovirol 2000; 6(Suppl 2):S101-8.
27. Agostini HT, Ryschkewitsch CF, Singer EJ, Stoner GL. JC virus regulatory region rearrangements and genotypes in progressive multifocal leukoencephalopathy: two independent aspects of virus variation. J Gen Virol 1997; 78:659-64. (Pubitemid 27116789)
28. Agostini HT, Ryschkewitsch CF, Stoner GL. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol 1996; 34:159-64. (Pubitemid 126506913)
29. Dubois V, Moret H, Lafon ME, et al. JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 2001; 183:213-7. (Pubitemid 32066021)
30. Ciappi S, Azzi A, De Santis R, et al. Archetypal and rearranged sequences of human polyomavirus JC transcription control region in peripheral blood leukocytes and in cerebrospinal fluid. J Gen Virol 1999; 80:1017-23. (Pubitemid 29179063)
31. Iida T, Kitamura T, Guo J, et al. Origin of JC polyomavirus variants associated with progressive multifocal leukoencephalopathy. Proc Natl Acad Sci U S A 1993; 90:5062-5. (Pubitemid 23182976)
32. Sala M, Vartanian JP, Kousignian P, et al. Progressive multifocal leukoencephalopathy in human immunodeficiency virus type 1-infected patients: absence of correlation between JC virus neurovirulence and polymorphisms in the transcriptional control region and the major capsid protein loci. J Gen Virol 2001; 82:899-907. (Pubitemid 32280049)
33. Agostini HT, Stoner GL. Amplification of the complete polyomavirus JC genome from brain, cerebrospinal fluid and urine using pre-PCR restriction enzyme digestion. J Neurovirol 1995; 1:316-20.
34. Cubitt CL, Cui X, Agostini HT, et al. Predicted amino acid sequences for 100 JCV strains. J Neurovirol 2001; 7:339-44. (Pubitemid 32894238)
35. Vaz B, Cinque P, Pickhardt M, Weber T. Analysis of the transcriptional control region in progressive multifocal leukoencephalopathy. J Neurovirol 2000; 6:398-409.
36. Ault GS. Activity of JC virus archetype and PML-type regulatory regions in glial cells. J Gen Virol 1997; 78:163-9. (Pubitemid 27067527)
37. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol 1984; 51:458-69. (Pubitemid 14091437)
38. Bauer PH, Bronson RT, Fung SC, et al. Genetic and structural analysis of a virulence determinant in polyomavirus VP1. J Virol 1995; 69:7925-31.
39. Bauer PH, Cui C, Liu WR, et al. Discrimination between sialic acid-containing receptors and pseudoreceptors regulates polyomavirus spread in the mouse. J Virol 1999; 73:5826-32. (Pubitemid 29274869)
40. Dubensky TW, Freund R, Dawe CJ, Benjamin TL. Polyomavirus replication in mice: influences of VP1 type and route of inoculation. J Virol 1991; 65:342-9.
41. Freund R, Garcea RL, Sahli R, Benjamin TL. A single-amino-acid substitution in polyomavirus VP1 correlates with plaque size and hemagglutination behavior. J Virol 1991; 65:350-5.
42. Agostini HT, Deckhut A, Jobes DV, et al. Genotypes of JC virus in East, central and Southwest Europe. J Gen Virol 2001; 82:1221-331. (Pubitemid 32454622)
43. Daniel AM, Swenson JJ, Mayreddy RP, Khalili K, Frisque RJ. Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Virology 1996; 216:90-101.
44. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:1067-74.